Illumina, Inc.
ILMN
Laboratory Analytical Instruments
Mkt Cap
$16.7BPE
-12.95Debt
-Cash
$1.108BEV
-FCF
$366MP/E Ratio
-12.95Debt
-Cash
$1.108BEV
-FCF
$366MCharts data: {"Earnings":[{"time":"2014-12-27","value":353351000},{"time":"2016-01-02","value":457390000},{"time":"2016-12-31","value":428090000},{"time":"2017-12-30","value":678000000},{"time":"2018-12-29","value":782000000},{"time":"2019-12-28","value":990000000},{"time":"2021-01-02","value":656000000},{"time":"2022-01-01","value":762000000},{"time":"2022-12-31","value":-4404000000},{"time":"2023-12-30","value":-1161000000}],"Sales":[{"time":"2014-12-27","value":1861358000},{"time":"2016-01-02","value":2219762000},{"time":"2016-12-31","value":2398373000},{"time":"2017-12-30","value":2752000000},{"time":"2018-12-29","value":3333000000},{"time":"2019-12-28","value":3543000000},{"time":"2021-01-02","value":3239000000},{"time":"2022-01-01","value":4526000000},{"time":"2022-12-31","value":4584000000},{"time":"2023-12-30","value":4504000000}],"Net Margins":[{"time":"2014-12-27","value":0.189835055910792},{"time":"2016-01-02","value":0.2060536219648773},{"time":"2016-12-31","value":0.17849183592377},{"time":"2017-12-30","value":0.24636627906976744},{"time":"2018-12-29","value":0.23462346234623463},{"time":"2019-12-28","value":0.279424216765453},{"time":"2021-01-02","value":0.20253164556962025},{"time":"2022-01-01","value":0.16836058329650905},{"time":"2022-12-31","value":-0.9607329842931938},{"time":"2023-12-30","value":-0.2577708703374778}],"Assets":[{"time":"2014-12-27","value":3339640000},{"time":"2016-01-02","value":3687747000},{"time":"2016-12-31","value":4280600000},{"time":"2017-12-30","value":5257000000},{"time":"2018-12-29","value":6959000000},{"time":"2019-12-28","value":7316000000},{"time":"2021-01-02","value":7585000000},{"time":"2022-01-01","value":15217000000},{"time":"2022-12-31","value":12252000000},{"time":"2023-12-30","value":10111000000}],"Stockholders Equity":[{"time":"2014-12-27","value":1462798000},{"time":"2016-01-02","value":1848553000},{"time":"2016-12-31","value":2270235000},{"time":"2017-12-30","value":2749000000},{"time":"2018-12-29","value":3845000000},{"time":"2019-12-28","value":4613000000},{"time":"2021-01-02","value":4694000000},{"time":"2022-01-01","value":10740000000},{"time":"2022-12-31","value":6599000000},{"time":"2023-12-30","value":5745000000}],"ROE":[{"time":"2014-12-27","value":0.24155830128288389},{"time":"2016-01-02","value":0.24743136929263052},{"time":"2016-12-31","value":0.18856638189438538},{"time":"2017-12-30","value":0.2466351400509276},{"time":"2018-12-29","value":0.20338101430429129},{"time":"2019-12-28","value":0.21461088228918274},{"time":"2021-01-02","value":0.13975287601193012},{"time":"2022-01-01","value":0.07094972067039106},{"time":"2022-12-31","value":-0.6673738445218973},{"time":"2023-12-30","value":-0.202088772845953}],"ROA":[{"time":"2014-12-27","value":0.15412170174030734},{"time":"2016-01-02","value":0.16955149038152564},{"time":"2016-12-31","value":0.13884946035602486},{"time":"2017-12-30","value":0.20544036522731596},{"time":"2018-12-29","value":0.13665756574220433},{"time":"2019-12-28","value":0.15992345544013123},{"time":"2021-01-02","value":0.11931443638760712},{"time":"2022-01-01","value":0.05809292238943287},{"time":"2022-12-31","value":-0.3410871694417238},{"time":"2023-12-30","value":-0.10572643655424785}]}
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
DCF
Discounted Cash Flow Valuation of Illumina, Inc.
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $366M | $333.5M | $303.9M | $276.9M | $252.3M | $229.9M | $209.5M | $190.9M | $174M | $158.5M | $144.5M | $1.445B |
| DCF | $290M | $229.8M | $182.1M | $144.3M | $114.3M | $90.58M | $71.78M | $56.87M | $45.06M | $35.71M | $357.1M | |
| Value | $1.618B | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth 9.4%
Earnings Stability 24%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 01-2016 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 01-2021 | 01-2022 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 21% | 18% | 25% | 23% | 28% | 20% | 17% | -96% | -26% | -29% |
| ROA | 17% | 14% | 21% | 14% | 16% | 12% | 5.8% | -34% | -11% | -11% |
| ROE | 25% | 19% | 25% | 20% | 21% | 14% | 7.1% | -67% | -20% | -22% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -5.56%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -17.76%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +0.45%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -7.93%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -4.01%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -13.55%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 01-2016 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 01-2021 | 01-2022 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | 2.11 | 2.45 | 2.11 | 2.36 | 1.36 | 1.33 | 2.95 | 21.08 | 0.00 | - |
| Debt Equity | 0.59 | 0.46 | 0.43 | 0.52 | 0.25 | 0.25 | 0.09 | 0.34 | 0.00 | - |
| MIN | ||||||||||
| Graham Stability | - | - | 100% | 100% | 100% | 80% | 94% | -550% | - | -550% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is 1.40.
What is the Graham’s Stability?
Graham’s Stability measure stands at -5.49.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 01-2021 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 9.4% | 6.2% | 12% | -1.7% | -1.4% |
| Net Income | - | - | - | - | -4.5% |
| Stockholders Equity | 14% | 8.4% | 7% | -13% | -2.7% |
| FCF | -5.7% | -20% | -32% | 170% | 2.6% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +6.21%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -1.4%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -4.51%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +8.36%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -2.73%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -19.67%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is +2.64%.